Interim analysis of a phase II trial of perioperative chemotherapy plus avelumab in esophagogastric and gastric adenocarcinoma

Alcindor, Thierry; Opu, T.; Mueller, Carmen L.; Marcus, Victoria; Fiset, Pierre‐Olivier; Camilleri-Broët, Sophie; Artho, Giovanni; Asselah, Jamil; Vanhuyse, Marie; Hickeson, Marc; Awan, Arif; Koulouris, Z.; Ferri, Lorenzo

doi:10.1093/annonc/mdz247.102

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…75 In the perioperative setting, encouraging safety and activity results have been recently reported from the interim analysis of a phase II trial testing avelumab plus chemotherapy in locally advanced gastric and esophagogastric adenocarcinoma (NCT03288350). 76…”

Section: Gastric Cancermentioning

confidence: 99%

Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies

Puccini

Battaglin

Iaia

et al. 2020

J Immunother Cancer

View full text Add to dashboard Cite

In the last few years, the unprecedented results of immune checkpoint inhibitors have led to a paradigm shift in clinical practice for the treatment of several cancer types. However, the vast majority of patients with gastrointestinal cancer do not benefit from immunotherapy. To date, microsatellite instability high and DNA mismatch repair deficiency are the only robust predictive biomarkers of response to immune checkpoint inhibitors. Unfortunately, these patients comprise only 5%–10% of all gastrointestinal cancers. Several mechanisms of both innate and adaptive resistance to immunotherapy have been recognized that may be at least in part responsible for the failure of immune checkpoint inhibitors in this population of patients. In the first part of this review article, we provide an overview of the main clinical trials with immune checkpoint inhibitors in patients with gastrointestinal cancer and the role of predictive biomarkers. In the second part, we discuss the actual body of knowledge in terms of mechanisms of resistance to immunotherapy and the most promising approach that are currently under investigation in order to expand the population of patients with gastrointestinal cancer who could benefit from immune checkpoint inhibitors.

show abstract

Section: Gastric Cancermentioning

confidence: 99%